John has over 25 years of business development experience with some of the industry’s premier companies, including Genentech, Genzyme, Millennium Pharmaceuticals, MPM Capital, Biogen and currently Novo Nordisk.
John has over 25 years of business development experience with some of the industry’s premier companies, including Genentech, Genzyme, Millennium Pharmaceuticals, MPM Capital, Biogen and currently Novo Nordisk.
Nouscom is a private oncology company developing next generation immunotherapies, founded in 2015 by an experienced management team that has worked together for many years in previous successful enterprises. Nouscom’s proprietary technology platform harnesses the full power of the immune response by combining viral vectored genetic vaccines based on neoantigens with other immunomodulators.

